Nanosyrinx raises £5m for intracellular drug delivery platform

The delivery of therapeutic proteins and peptides directly into the cytosol of target cells is the core challenge addressed by Coventry-based Nanosyrinx Ltd. The company has developed a synthetic biology platform known as the Nanosyringe to provide transport solutions for biologic drugs. Pharmaceutical and biotechnology companies that require specialized mechanisms for the intracellular administration of these treatments serve as the primary customer base for the technology.

Filings processed in September 2026 indicate the business has secured an estimated £5m in new funding, with the allotment of shares also occurring during the same month. This latest round follows a total of £1.7m raised by the company during 2025.

The organization was incorporated in 2018. Financial data from the year ended 31 December 2024 shows that Nanosyrinx Ltd operated with a team of 18 employees.